Beyond Borders: A Global Analysis of Parkinson's Disease and Future Treatment Prospects 2023-2032

News provided by

Jul 28, 2023, 10:45 ET

DUBLIN, July 28, 2023 /PRNewswire/ -- The "Parkinson's Disease: Market Insights, Epidemiology, and Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.

This report presents a detailed analysis of PD, covering its epidemiology, market trends, and emerging treatment options across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Epidemiology Insights: The report provides a comprehensive understanding of PD's epidemiology, including historical and forecasted data on diagnosed prevalent cases, gender-specific cases, age-specific cases, and stage-specific cases in the 7MM. In 2022, the United States had the highest number of diagnosed PD cases, estimated at approximately 1.2 million. The EU4 and the UK collectively reported around 1.2 million diagnosed cases, while Japan accounted for 0.2 million cases.

Market Insights: The market size of Parkinson's Disease in 2022 was the largest in the US, reaching approximately USD 1,820 million in the 7MM. In contrast, the United Kingdom had the lowest market size, with USD 135 million. Over the forecast period (2023-2032), the market is expected to witness significant growth due to the introduction of emerging therapies such as Tavapadon, P2B001, BIIB122, ABBV-951, Buntanetap, IPX203, NE3107, CVN424, ITI-214, and CNM-Au8.

Current Treatment Scenario and Emerging Therapies: Current treatment options for PD include levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine, anticholinergics, and adenosine A2a antagonists. While these medications manage symptoms, they do not halt disease progression. Promising emerging therapies like Tavapadon, P2B001, BIIB122, ABBV-951, and Buntanetap are expected to revolutionize PD management, offering improved outcomes for patients.

Geographical Coverage: The report extensively covers PD insights in the United States, EU4, the UK, and Japan, highlighting regional variations in disease prevalence, treatment practices, and market trends.

Parkinson's Disease Market Outlook: The market size of Parkinson's Disease in the 7MM was approximately USD 3,226 million in 2022. It is projected to grow at a CAGR of 11.2% during the forecast period, driven by the increasing diagnosed prevalent cases and the introduction of novel therapies.

Pipeline Development Activities: The report offers insights into ongoing clinical trials and emerging therapeutic candidates in Phase III and Phase II, providing a glimpse of the future landscape of PD treatment.

Market Access and Reimbursement: A comprehensive assessment of market access and reimbursement policies, cost-effectiveness, and patient assistance programs sheds light on the challenges faced by patients in accessing expensive therapies.

KOL Views: Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) in the field of PD provide valuable insights, validating treatment patterns, patient preferences, and challenges in the current treatment landscape.

Conclusion: Parkinson's Disease presents a significant healthcare burden globally, necessitating a thorough understanding of its epidemiology and treatment landscape. With emerging therapies on the horizon, the future holds promising advancements in PD management, enhancing patients' quality of life. This report equips stakeholders with critical information to make informed decisions, address unmet needs, and create effective disease management strategies. Through collaborative efforts and innovative treatments, we can strive towards better outcomes for individuals living with Parkinson's Disease and their families.

Key Topics Covered:

1. Key Insights
2. Report Introduction
3. Parkinson's disease Market Overview at a Glance
4. Executive Summary of Parkinson's disease
5. Key Events
6. Epidemiology and Market Methodology
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Products
11. Emerging Therapies
12. Parkinson's disease: The 7MM Analysis
13. KOL Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Acronyms and Abbreviations
18. Appendix

A selection of companies mentioned in this report includes:

Cerevel Therapeutics
Pfizer
Pharma Two B
AbbVie
Biogen
Denali Therapeutics
Annovis Bio
Amneal Pharmaceuticals
BioVie
Cerevance
Clene Nanomedicine
Intra-Cellular Therapies
Hoffmann-La Roche
Prothena Corporation

For more information about this report visit https://www.researchandmarkets.com/r/ygapx

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets